Skip to main content
Menu
US

AlphaLISA Human CTLA4 / CD80 Binding Kit, 500 Assay Points

The AlphaLISA™ CTLA-4/CD80 binding kit is designed for the detection of binding activity between human CTLA-4 and CD80, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Protein-Protein Interaction
Sample Volume 10 µL

The AlphaLISA™ CTLA-4/CD80 binding kit is designed for the detection of binding activity between human CTLA-4 and CD80, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 500 Assay Points
Part #:
AL3046C
List Price
USD 2,833.00
Unit Size: 5,000 Assay Points
Part #:
AL3046F
List Price
USD 17,310.00

Overview

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad range of affinities
  • High avidity
  • Results in less than 3 hours
  • Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated CD80 binds to the Streptavidin-coated Alpha Donor beads, while His tagged CTLA-4 is captured by Anti-His AlphaLISA Acceptor beads. When CD80 binding to CTLA-4 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Human Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of differentiation 152), is a cell membrane receptor and a member of immunoglobulin superfamily. CTLA-4 is expressed once a T cell becomes active and modulates T cell signals by blocking the CD80 (B7.1) and CD86 (B7.2) ligands from binding to CD28. CTLA-4, functioning as an immune checkpoint, downregulates T cell immune responses. Because of its profound inhibitory role blocking CTLA-4 and CD80 or CD86 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.

Specifications

Application
Protein-Protein Interaction
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Product Group
Kit
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
CTLA4,CD80
Target Class
Binding Assay
Target Species
Human
Technology
Alpha
Therapeutic Area
Immuno-oncology
Unit Size
500 Assay Points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-3 of 3 Resources
Guide Icon
Guide
Get your white paper about current therapies in Immuno-oncology

A single White Paper for a review of immuno-oncology

Immuno-oncology, the field which stimulates a individual's own immunity in...

Flyer Icon
Flyer
Reagent solutions for autoimmunity research.

Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies

Flyer Icon
Flyer
Solutions to advance your CART-T cell research

Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...

Scroll Icon